The ultimate interest of biomedical research is the study of humans and the goal is the improvement of human health. However, research on humans is severely compromised by the inability to perform invasive experimental work in order to establish the cause and effect relationships between processes. Mouse models play an important role in characterizing key aspects of the driving forces of malignant transformation and disease in humans. However, they rarely represent the genetic complexity and clinicopathologic characteristics of human disease. Xenotransplantation of human cells into mice is regularly used to study the biology of human cancer and test the efficacy of novel anti-cancer therapies in vivo. But its value is limited because scientists are currently mainly limited to aggressively growing primary tumors or cell lines that are less susceptible to xenorejection and less dependent on critical signals provided by the microenvironment. Therefore there is an unmet need to develop methods to reliably grow primary human tumor cells in mice. In the here proposed project, humanization of the microenvironment will be achieved by replacement and controlled expression of essential, but not cross-reactive, growth and survival factors in the mouse genome with their human counterparts. Furthermore, novel approaches to reduce xenorejection by myeloid cells and to generate space in the bone marrow niche complete the proposed genetic manipulations. These novel in vivo models will then be used to test and compare as a benchmark acute myeloid leukemia (AML) engraftment, and to establish models for primary chronic myeloid leukemia and myeloproliferative neoplasias, as well as multiple myeloma - diseases in which the lack of in vivo models faithfully reflecting these diseases curtails research. Successful establishment of these models would allow detailed studies of biology as well as validation of approved and experimental therapies. The development of a versatile platform allowing the study of human primary malignancies in vivo in genetically modified mice would represent a major advance for the field. In summary, this model will serve as platform for preclinical therapy testing with increased predictive value and allow studies on biology of the dynamic evolution of neoplasias with an immediate impact on clinical practice.
Novel and innovative therapeutics are urgently needed to decrease mortality in cancer, but a fundamental missing link in current research in many blood cancers like leukemias and lymphomas, is the ability to study primary human tumor cells in their natural setting, which we call a microenvironment. We propose to develop a versatile platform that allows the study of human cancers in vivo by generating mice which provide a microenvironment like the one in the human body. This model will serve as a platform for preclinical testing of medicines against cancer with a better likelihood of how well these medicines will work in people.
|Yu, Hua; Borsotti, Chiara; Schickel, Jean-Nicolas et al. (2017) A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. Blood 129:959-969|
|Saito, Yasuyuki; Ellegast, Jana M; Rafiei, Anahita et al. (2016) Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice. Blood 128:1829-1833|
|Das, Rituparna; Strowig, Till; Verma, Rakesh et al. (2016) Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat Med 22:1351-1357|
|Nair, Shiny; Branagan, Andrew R; Liu, Jun et al. (2016) Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med 374:555-61|
|Ellegast, Jana M; Rauch, Philipp J; Kovtonyuk, Larisa V et al. (2016) inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice. Blood 128:2130-2134|
|Theocharides, Alexandre P A; Rongvaux, Anthony; Fritsch, Kristin et al. (2016) Humanized hemato-lymphoid system mice. Haematologica 101:5-19|
|Nair, Shiny; Boddupalli, Chandra Sekhar; Verma, Rakesh et al. (2015) Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood 125:1256-71|
|Rongvaux, Anthony; Willinger, Tim; Martinek, Jan et al. (2014) Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 32:364-72|
|Sehgal, Kartik; Dhodapkar, Kavita M; Dhodapkar, Madhav V (2014) Targeting human dendritic cells in situ to improve vaccines. Immunol Lett 162:59-67|
|Sehgal, Kartik; Ragheb, Ragy; Fahmy, Tarek M et al. (2014) Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. J Immunol 193:2297-305|
Showing the most recent 10 out of 11 publications